Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
A phase 2 trial of 2X-121 in ovarian cancer, run by Allarity Therapeutics, now recruiting.
Overview
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer is a phase 2 interventional study registered as NCT03878849 by Allarity Therapeutics, with 40 participants planned, started 2019-04-15 and due to reach its primary completion in 2027-03. Interventions recorded: 2X-121.
Similar pages
not linked directly; found by shared links- TrialA Trial of Vigil for Participants With Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialCancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialA Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Shares Ovarian cancer and the tag pipeline.
- TrialA Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialEffect of Theronomic Ova-All Care on Biomarkers of Ovarian Health in Adult Female With Polycystic Ovarian Syndrome
Shares Ovarian cancer and the tag pipeline.
- TrialTrial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Shares Ovarian cancer and the tag pipeline.
- TrialDual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Shares Ovarian cancer and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Ovarian cancer and the tag pipeline.